Raksha Jain

Raksha Jain

Auto-generated profile, based on publicly available information

Raksha Jain

University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
PMPeter Middleton
Peter Middleton
MMMarcus A. Mall
Marcus A. Mall
PDPavel Dřevínek
Pavel Dřevínek
LLLarry C. Lands
Larry C. Lands
EMEdward F. McKone
Edward F. McKone
RJRaksha Jain
Raksha Jain
Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation. In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del–minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clinical outcomes.

1 December 2014 in Journal of Women's Health
Verified
Journal Article
Closed access
CHCayce L. Harness-Brumley
Cayce L. Harness-Brumley
AEAlan C. Elliott
Alan C. Elliott
DRDaniel B. Rosenbluth
Daniel B. Rosenbluth
DRDeepa Raghavan
Deepa Raghavan
RJRaksha Jain
Raksha Jain
Background: Cystic fibrosis (CF) is a common life-shortening genetic disease in which women have been described to have worse outcomes than males, particularly in response to respiratory infections with Pseudomonas aeruginosa . However, as advancements in therapies have improved life expectancy, this gender disparity has been challenged. The objective of this study is to examine whether a gender-based survival difference still exists in this population and determine the impact of common CF respiratory infections on outcomes in males versus females with CF. Methods: We conducted a retrospective cohort analysis of 32,766 patients from the United States Cystic Fibrosis Foundation Patient Registry over a 13-year period. Kaplan-Meier and Cox proportional hazards models were used to compare overall mortality and pathogen based survival rates in males and females. Results: Females demonstrated a decreased median life expectancy (36.0 years; 95% confidence interval [CI] 35.0–37.3) compared with men (38.7 years; 95% CI 37.8–39.6; p <0.001). Female gender proved to be a significant risk factor for death (hazard ratio 2.22, 95% CI 1.79–2.77), despite accounting for variables known to influence CF mortality. Women were also found to become colonized earlier with several bacteria and to have worse outcomes with common CF pathogens. Conclusions: CF women continue to have a shortened life expectancy relative to men despite accounting for key CF-related comorbidities. Women also become colonized with certain common CF pathogens earlier than men and show a decreased life expectancy in the setting of respiratory infections. Explanations for this gender disparity are only beginning to be unraveled and further investigation into mechanisms is needed to help develop therapies that may narrow this gender gap.

1 April 2012 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
RJRaksha Jain
Raksha Jain
JRJennifer M. Ray
Jennifer M. Ray
JPJie-Hong Pan
Jie-Hong Pan
SBSteven L. Brody
Steven L. Brody
Previous studies have demonstrated a female disadvantage in airway diseases, such as asthma and bronchiectasis. The basis for this sex disparity is unknown. We hypothesized that the female sex hormone, progesterone (P4), inhibits functions of the normal airway mucociliary apparatus. P4 receptor (PR) expression was evaluated in human lung and cultured primary human airway epithelial cells isolated from male and female lung transplant donors. PR expression was restricted to the proximal region of the cilia of airway epithelia, and was similar in men and women. Expression of isoform PR-B was more abundant than PR-A in cells from both sexes. Airway epithelial cell exposure to P4 decreased cilia beat frequency (CBF) by 42.3% (±7.2). Inhibition of CBF was prevented by coadministration of P4 with the active form of estrogen, 17β-estradiol, or the PR antagonist, mifepristone. P4 inhibition was time and dose dependent, with a significant decrease by 8 hours and maximal effect at 24 hours, accompanied by translocation of PR from the cilia to the nucleus. Inhibition of cilia beat was also prevented by treatment of cells with actinomycin D, suggesting that CBF inhibition is a transcriptionally mediated event. Together, these findings indicate that sex hormones influence the function of a key component of the mucociliary apparatus. These mechanisms may contribute to the sex disparity present in airway diseases and provide therapeutic targets for the treatment of these debilitating airway diseases.


18 December 2015 in Respirology
Verified
Journal Article
Closed access
PDF file
DRDeepa Raghavan
Deepa Raghavan
RJRaksha Jain
Raksha Jain

1 July 2018 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
RJRaksha Jain
Raksha Jain
VBV.V. Beckett
V.V. Beckett
MKM.W. Konstan
M.W. Konstan
FAF.J. Accurso
F.J. Accurso
JBJ.L. Burns
J.L. Burns
JCJ.F. Chmiel
J.F. Chmiel